{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:38:56Z","timestamp":1788316736807,"version":"build-2803163510"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40620-019-00614-1","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T05:09:36Z","timestamp":1557810576000},"page":"883-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-2141","authenticated-orcid":false,"given":"Filippo","family":"Mariano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"614_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Ponto","year":"1990","unstructured":"Ponto LL, Schoenwald RD (1990) Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (part I). Clin Pharmacokinet 18:381\u2013408. https:\/\/doi.org\/10.2165\/00003088-199018050-00004","journal-title":"Clin Pharmacokinet"},{"key":"614_CR2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1681\/ASN.V1161100","volume":"11","author":"R Agarwal","year":"2000","unstructured":"Agarwal R, Gorski JC, Sundblad K, Brater D (2000) Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 11:1100\u20131105","journal-title":"J Am Soc Nephrol"},{"key":"614_CR3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1681\/ASN.V133798","volume":"13","author":"CS Wilcox","year":"2002","unstructured":"Wilcox CS (2002) New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798\u2013805","journal-title":"J Am Soc Nephrol"},{"key":"614_CR4","unstructured":"The 2008 Prohibited List (2008) World anti-doping code. www.wada-ama.org\/sites\/default\/files\/resources\/files\/WADA-prohibited-list-2014-EN.pdf . Accessed 19 Apr 2019"},{"key":"614_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jvim.12593","volume":"29","author":"KW Hinchcliff","year":"2015","unstructured":"Hinchcliff KW, Couetil LL, Knight PK, Morley PS, Robinson NE, Sweeney CR, van Erck E (2015) Exercise induced pulmonary hemorrhage in horses: American College of Veterinary Internal Medicine Consensus Statement. J Vet Intern Med 29:743\u2013758. https:\/\/doi.org\/10.1111\/jvim.12593","journal-title":"J Vet Intern Med"},{"key":"614_CR6","unstructured":"Sturm K, Siedel W, Weyer R (1962) Sulphamoylanthranilic acids, FRG patent 1,122,541 (CA 56:14032-33, 1962)"},{"key":"614_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/pharmacy6020043","volume":"6","author":"A Fuentes","year":"2018","unstructured":"Fuentes A, Pineda M, Venkata K (2018) Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy 6:43. https:\/\/doi.org\/10.3390\/pharmacy6020043","journal-title":"Pharmacy"},{"key":"614_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1021\/es050991m","volume":"40","author":"S Castiglioni","year":"2006","unstructured":"Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E (2006) Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol 40:357\u2013363. https:\/\/doi.org\/10.1021\/es050991m","journal-title":"Environ Sci Technol"},{"key":"614_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.scitotenv.2008.10.016","volume":"407","author":"H Khalaf","year":"2009","unstructured":"Khalaf H, Salste L, Karlsson P, Ivarsson P, Jass J, Olsson PE (2009) In vitro analysis of inflammatory responses following environmental exposure to pharmaceuticals and inland waters. Sci Total Environ 407:1452\u20131460. https:\/\/doi.org\/10.1016\/j.scitotenv.2008.10.016","journal-title":"Sci Total Environ"},{"key":"614_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mas","volume":"26","author":"SW Thevis Mario","year":"2007","unstructured":"Thevis Mario SW (2007) Mass spectrometry in sports drug testing: structure characterization and analystical assays. Mass Spectrom Rev 26:79\u2013107. https:\/\/doi.org\/10.1002\/mas","journal-title":"Mass Spectrom Rev"},{"key":"614_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/FTD.0b013e3182a8997c","volume":"36","author":"M Leporati","year":"2014","unstructured":"Leporati M, Bua RO, Mariano F, Carignano P, Stella M, Biancone L, Vincenti M (2014) Determination by LC\u2013MS\/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 36:182\u2013191. https:\/\/doi.org\/10.1097\/FTD.0b013e3182a8997c","journal-title":"Ther Drug Monit"},{"key":"614_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chroma.2006.09.034","volume":"1135","author":"V Morra","year":"2006","unstructured":"Morra V, Davit P, Capra P, Vincenti M, Di Stilo A, Botr\u00e8 F (2006) Fast gas chromatographic\/mass spectrometric determination of diuretics and masking agents in human urine. Development and validation of a productive screening protocol for antidoping analysis. J Chromatogr A 1135:219\u2013229","journal-title":"J Chromatogr A"},{"key":"614_CR13","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/jssc.200500387","volume":"29","author":"C Brunelli","year":"2006","unstructured":"Brunelli C, Bicchi C, Di Stilo A, Salomone A, Vincenti M (2006) High-speed gas-chromatography in doping control: fast-GC and Fast-GC\/MS determination of beta-adrenoceptor ligands and diuretics. J Sep Scie 29:2765\u20132771","journal-title":"J Sep Scie"},{"key":"614_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jpba.2008.07.003","volume":"48","author":"M Espinosa Bosch","year":"2008","unstructured":"Espinosa Bosch M, Ruiz Sanchez AJ, Sanchez Rojas R, Bosch Ojeda C (2008) Recent developments in analytical determinations of furosemide. J Pharm Biomed Anal 48:519\u2013532","journal-title":"J Pharm Biomed Anal"},{"key":"614_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/BF00606681","volume":"15","author":"RE Cutler","year":"1974","unstructured":"Cutler RE, Forrey AW, Christopher TGKB (1974) Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15:588\u2013596. https:\/\/doi.org\/10.1007\/BF00606681","journal-title":"Clin Pharmacol Ther"},{"key":"614_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2165\/00003088-199018060-00003","volume":"18","author":"LLB Ponto","year":"1990","unstructured":"Ponto LLB, Schoenwald RD (1990) Furosemide (Frusemide) a pharmacokinetic\/pharmacodynamic review (part II). Clin Pharmacokinet 18:460\u2013471","journal-title":"Clin Pharmacokinet"},{"key":"614_CR17","first-page":"127","volume":"11","author":"LP Rybak","year":"1982","unstructured":"Rybak LP (1982) Pathophysiology of furosemide ototoxicity. J Otolaryngol 11:127\u2013133","journal-title":"J Otolaryngol"},{"key":"614_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/03005368209081455","volume":"16","author":"A Forge","year":"1982","unstructured":"Forge A, Brown AM (1982) Ultrastructural and electrophysiological studies of acute ototoxic effects of furosemide. Br J Audiol 16:109\u2013116","journal-title":"Br J Audiol"},{"key":"614_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0385-8146(12)80116-7","volume":"20","author":"A Hara","year":"1993","unstructured":"Hara A, Machiki K, Senarita M, Komeno M, Kusakari J (1993) Pharmacokinetics of furosemide in endolymph. Auris Nasus Larynx 20:247\u2013254","journal-title":"Auris Nasus Larynx"},{"key":"614_CR20","first-page":"537","volume":"216","author":"TP Green","year":"1981","unstructured":"Green TP, Rybak LP, Mirkin BL, Juhn SK, Morizono T (1981) Pharmacologic determinants of ototoxicity of furosemide in the chinchilla. J Pharmacol Exp Ther 216:537\u2013542","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"614_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/lio2.108)","volume":"25","author":"F Santos","year":"2017","unstructured":"Santos F, Nadol JB (2017) Temporal bone histopathology of furosemide ototoxicity. Laryngoscope Investig Otolaryngol 25(2):204\u2013207. https:\/\/doi.org\/10.1002\/lio2.108)","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"614_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF00613429","volume":"9","author":"B Beermann","year":"1975","unstructured":"Beermann B, Dal\u00e9n E, Lindstr\u00f6m B, Ros\u00e9n A (1975) On the fate of furosemide in man. Eur J Clin Pharmacol 9:57\u201361. https:\/\/doi.org\/10.1007\/BF00613429","journal-title":"Eur J Clin Pharmacol"},{"key":"614_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cpt197722170","volume":"22","author":"B Beermann","year":"1977","unstructured":"Beermann B, Dal\u00e9n E, Lindstr\u00f6m B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22:70\u201378. https:\/\/doi.org\/10.1002\/cpt197722170","journal-title":"Clin Pharmacol Ther"},{"key":"614_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/bdd","volume":"35","author":"SA Van Wart","year":"2014","unstructured":"Van Wart SA, Shoaf SE, Mallikaarjun S (2014) Population-based meta-analysis of furosemide pharmacokinetics. Biopharm Drug Dispos 35:119\u2013133. https:\/\/doi.org\/10.1002\/bdd","journal-title":"Biopharm Drug Dispos"},{"key":"614_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cpt1974164659","volume":"16","author":"CM Huang","year":"1974","unstructured":"Huang CM, Atkinson AJ Jr, Levin M, Levin NW, Quintanilla A (1974) Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16:659\u2013666. https:\/\/doi.org\/10.1002\/cpt1974164659","journal-title":"Clin Pharmacol Ther"},{"key":"614_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1476-5381.1996.tb15755.x","volume":"119","author":"V Pichette","year":"1996","unstructured":"Pichette V, Geadah D, Du Souich P (1996) The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. Br J Phamacol 119:885\u2013890","journal-title":"Br J Phamacol"},{"key":"614_CR27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.V72345","volume":"7","author":"V Pichette","year":"1996","unstructured":"Pichette V, Du Souich P (1996) Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol 7:345\u2013349","journal-title":"J Am Soc Nephrol"},{"key":"614_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1211\/0022357991772402","volume":"51","author":"TB Vree","year":"1999","unstructured":"Vree TB, Van der Ven AJ (1999) Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans. J Pharm Pharmacol 51:239\u2013248. https:\/\/doi.org\/10.1211\/0022357991772402","journal-title":"J Pharm Pharmacol"},{"key":"614_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","volume":"76","author":"O Kerdpin","year":"2008","unstructured":"Kerdpin O, Knights KM, Elliot DJ, Miners JO (2008) In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem Pharmacol 76:249\u2013257. https:\/\/doi.org\/10.1016\/j.bcp.2008.04.014","journal-title":"Biochem Pharmacol"},{"key":"614_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1681\/ASN.2014070724","volume":"26","author":"JA Kellum","year":"2015","unstructured":"Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G (2015) Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol 26:2231\u20132238. https:\/\/doi.org\/10.1681\/ASN.2014070724","journal-title":"J Am Soc Nephrol"},{"key":"614_CR31","doi-asserted-by":"publisher","unstructured":"(2012) Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2(Suppl):1\u2013138. https:\/\/doi.org\/10.1038\/kisup.2012.7","DOI":"10.1038\/kisup.2012.7"},{"key":"614_CR32","first-page":"90","volume":"15","author":"CB Brown","year":"1981","unstructured":"Brown CB, Ogg CS, Cameron J (1981) High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 15:90\u201396","journal-title":"Clin Nephrol"},{"key":"614_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.joto.2016.10.001","volume":"11","author":"D Ding","year":"2016","unstructured":"Ding D, Liu H, Qi W, Jiang H, Li Y, Wu X, Sun H, Gross K, Salvi R (2016) Ototoxic effects and mechanisms of loop diuretics. J Otol 11:145\u2013156","journal-title":"J Otol"},{"key":"614_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1517\/14740338.5.3.383","volume":"5","author":"JG Yorgason","year":"2006","unstructured":"Yorgason JG, Fayad JN, Kalinec F (2006) Understanding drug ototoxicity: molecular insights for prevention and clinical management. Expert Opin Drug Saf 5:383\u2013399","journal-title":"Expert Opin Drug Saf"},{"key":"614_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10162-014-0458-8","volume":"15","author":"K Hirose","year":"2014","unstructured":"Hirose K, Li SZ, Ohlemiller KK, Ransohoff RM (2014) Systemic lipopolysaccharide induces cochlear inflammation and exacerbates the synergistic ototoxicity of kanamycin and furosemide. J Assoc Res Otolaryngol 15:555\u2013570","journal-title":"J Assoc Res Otolaryngol"},{"key":"614_CR36","doi-asserted-by":"publisher","first-page":"e923","DOI":"10.1097\/CCM.0000000000001823","volume":"44","author":"BI Silbert","year":"2016","unstructured":"Silbert BI, Ho KM, Lipman J, Roberts JA, Corcoran TB, Morgan DJ, Pavey W, Mas E, Barden AE, Mori TA (2016) Determinants of urinary output response to IV furosemide in acute kidney injury: a pharmacokinetic\/pharmacodynamic study. Crit Care Med 44:e923\u2013e929. https:\/\/doi.org\/10.1097\/CCM.0000000000001823","journal-title":"Crit Care Med"},{"key":"614_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40620-018-0537-8","volume":"31","author":"F Mariano","year":"2018","unstructured":"Mariano F, Leporati M, Carignano P, Stella M, Vincenti M, Biancone L (2018) Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration. J Nephrol 31:889\u2013897. https:\/\/doi.org\/10.1007\/s40620-018-0537-8","journal-title":"J Nephrol"},{"key":"614_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1254\/jphs.09339SC","volume":"308","author":"H Hasannejad","year":"2004","unstructured":"Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H (2004) Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308:1021\u20131029. https:\/\/doi.org\/10.1254\/jphs.09339SC","journal-title":"J Pharmacol Exp Ther"},{"key":"614_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cpt1977212141","volume":"21","author":"HJ Rose","year":"1977","unstructured":"Rose HJ, O\u2019Malley K, Pruitt AW (1977) Depression of renal clearance of furosemide in man by azotemia. Clin Pharmacol Ther 21:141\u2013146","journal-title":"Clin Pharmacol Ther"},{"key":"614_CR40","first-page":"636","volume":"237","author":"J Bidiville","year":"1986","unstructured":"Bidiville J, Roch-Ramel F (1986) Competition of organic anions for furosemide and p-aminohippurate secretion in the rabbit. J Pharmacol Exp Ther 237:636\u2013643","journal-title":"J Pharmacol Exp Ther"},{"key":"614_CR41","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00467-006-0224-1","volume":"21","author":"JL Reyes","year":"2006","unstructured":"Reyes JL, Aldana I, Barbier O, Parrales AA, Melendez E (2006) Indomethacin decreases furosemide-induced natriuresis and diuresis on the neonatal kidney. Pediatr Nephrol 21:1690\u20131697. https:\/\/doi.org\/10.1007\/s00467-006-0224-1","journal-title":"Pediatr Nephrol"},{"key":"614_CR42","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/ndt\/gfr541","volume":"27","author":"M Kunin","year":"2012","unstructured":"Kunin M, Holtzman EJ, Melnikov S, Dinour D (2012) Urinary organic anion transporter protein profiles in AKI. Nephrol Dial Transpl 27:1387\u20131395. https:\/\/doi.org\/10.1093\/ndt\/gfr541","journal-title":"Nephrol Dial Transpl"},{"key":"614_CR43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1681\/ASN.2006050454","volume":"18","author":"C Schmidt","year":"2007","unstructured":"Schmidt C, Hocherl K, Schweda F et al (2007) Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 18:1072\u20131083. https:\/\/doi.org\/10.1681\/ASN.2006050454","journal-title":"J Am Soc Nephrol"},{"key":"614_CR44","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1097\/01.CCM.0000239119.57544.0C","volume":"34","author":"MJ Dubois","year":"2006","unstructured":"Dubois MJ, Orellana-Jimenez C, Melot C et al (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med 34:2536\u20132540. https:\/\/doi.org\/10.1097\/01.CCM.0000239119.57544.0C","journal-title":"Crit Care Med"},{"key":"614_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/912839","volume":"2015","author":"CJ Wiedermann","year":"2015","unstructured":"Wiedermann CJ, Joannidis M (2015) Nephroprotective potential of human albumin infusion: a narrative review. Gastroenterol Res Pract 2015:1\u20138. https:\/\/doi.org\/10.1155\/2015\/912839","journal-title":"Gastroenterol Res Pract"},{"key":"614_CR46","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/01.CCM.0000171539.47006.02","volume":"33","author":"GS Martin","year":"2005","unstructured":"Martin GS, Moss M, Wheeler AP et al (2005) A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 33:1681\u20131687. https:\/\/doi.org\/10.1097\/01.CCM.0000171539.47006.02","journal-title":"Crit Care Med"},{"key":"614_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2369-13-92","volume":"13","author":"B Phakdeekitcharoen","year":"2012","unstructured":"Phakdeekitcharoen B, Boonyawat K (2012) The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study. BMC Nephrol 13:1\u20139. https:\/\/doi.org\/10.1186\/1471-2369-13-92","journal-title":"BMC Nephrol"},{"key":"614_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jcrc.2013.10.004","volume":"29","author":"GD Kitsios","year":"2014","unstructured":"Kitsios GD, Mascari P, Ettunsi R, Gray AW (2014) Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care 29:253\u2013259. https:\/\/doi.org\/10.1016\/j.jcrc.2013.10.004","journal-title":"J Crit Care"},{"key":"614_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5502-4","author":"M Joannidis","year":"2019","unstructured":"Joannidis M, Klein SJ, Ostermann M (2019) 10 myths about frusemide. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-018-5502-4","journal-title":"Intensive Care Med"},{"key":"614_CR50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/00003246-199408000-00017","volume":"22","author":"SJ Danziger","year":"1994","unstructured":"Danziger SJ, Martin L (1994) Continuous infusion of loop diuretics in the critically ill: a review of the literature. Crit Care Med 22:1323\u20131329","journal-title":"Crit Care Med"},{"key":"614_CR51","doi-asserted-by":"publisher","DOI":"10.1159\/000108641","author":"M Ostermann","year":"2007","unstructured":"Ostermann M, Alvarez G, Sharpe MD, Martin CM (2007) Frusemide administration in critically ill patients by continuous compared to bolus therapy. Nephron Clin Pract. https:\/\/doi.org\/10.1159\/000108641","journal-title":"Nephron Clin Pract"},{"key":"614_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/0000102089","volume":"156","author":"SM Bagshaw","year":"2007","unstructured":"Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R et al (2007) Diuretics in the management of acute kidney injury: a multinational survey. Contrib Nephrol 156:236\u2013249. https:\/\/doi.org\/10.1159\/0000102089","journal-title":"Contrib Nephrol"},{"key":"614_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.22514\/SV62.102011.8","volume":"6","author":"A Zangrillo","year":"2011","unstructured":"Zangrillo A, Cabrini L, Monti G et al (2011) Continuous infusion versus bolus injection of furosemide in critically ill patients. A systematic review and meta-analysis. Signa Vitae 6:58\u201363. https:\/\/doi.org\/10.22514\/SV62.102011.8","journal-title":"Signa Vitae"},{"key":"614_CR54","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1053\/j.jvca.2018.01.004","volume":"32","author":"KT Ng","year":"2018","unstructured":"Ng KT, Velayit A, Khoo DKY, Mohd Ismail A, Mansor M (2018) Continuous infusion versus intermittent bolus injection of furosemide in critically Ill patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 32:2303\u20132310. https:\/\/doi.org\/10.1053\/j.jvca.2018.01.004","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"614_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11739-014-1112-5","volume":"10","author":"A Palazzuoli","year":"2014","unstructured":"Palazzuoli A, Pellegrini M, Franci B (2014) Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Intern Emerg Med 10:41\u201349. https:\/\/doi.org\/10.1007\/s11739-014-1112-5","journal-title":"Intern Emerg Med"},{"key":"614_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/0974-2700.150395","volume":"8","author":"DD Yeh","year":"2015","unstructured":"Yeh DD, Van Der Wilden GM, Cropano C, Chang Y, King DR, De Moya M, Fagenholz P, Kaafarani H, Lee J, Velmahos G (2015) Goal-directed diuresis: a case\u2014control study of continuous furosemide infusion in critically ill trauma patients. J Emerg Trauma Shock 8:34. https:\/\/doi.org\/10.4103\/0974-2700.150395","journal-title":"J Emerg Trauma Shock"},{"key":"614_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/tcic.8.6.273.276","volume":"8","author":"N Makhoul","year":"1997","unstructured":"Makhoul N, Riad T, Friedstrom S, Zveibil FR (1997) Frusemide in pulmonary oedema: continuous versus intermittent. Clin Intensive Care 8:273\u2013276","journal-title":"Clin Intensive Care"},{"key":"614_CR58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jcrc.2013.10.009","volume":"29","author":"MY Wu","year":"2014","unstructured":"Wu MY, Chang NC, Su CL, Hsu YH, Chen TW, Lin YF, Wu CH, Tam KW (2014) Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care 29:2\u20139. https:\/\/doi.org\/10.1016\/j.jcrc.2013.10.009","journal-title":"J Crit Care"},{"key":"614_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcrc.2013.03.015","volume":"29","author":"F Alqahtani","year":"2014","unstructured":"Alqahtani F, Koulouridis I, Susantitaphong PA (2014) A meta-analysis of continuous vs intermittent infusion of loop diuretics in hospitalized patients. J Crit Care 29:10\u201317. https:\/\/doi.org\/10.1016\/j.jcrc.2013.03.015","journal-title":"J Crit Care"},{"key":"614_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/14651858.CD003178.pub3","volume":"5","author":"DRK Salvador","year":"2005","unstructured":"Salvador DRK, Punzalan FE, Rey NR, Punzalan FE (2005) Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 5:6. https:\/\/doi.org\/10.1002\/14651858.CD003178.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"614_CR61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/nejmoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O\u2019Connor CM, NHLBI Heart Failure Clinical Research Network (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797\u2013805. https:\/\/doi.org\/10.1056\/nejmoa1005419","journal-title":"N Engl J Med"},{"issue":"10","key":"614_CR62","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2018.04.00863","volume":"6","author":"K Sharma","year":"2018","unstructured":"Sharma K, Vaishnav J, Kalathiya R, Hu JR, Miller J, Shah N, Hill T, Sharp M, Tsao A, Alexander KM, Gupta R, Montemayor K, Kovell L, Chasler JE, Lee YJ, Fine DM, Kass DA, Weiss RG, Thiemann DR, Ndumele CE, Schulman SP, Russell SD, Housestaff Osler Medical (2018) Randomized evaluation of heart failure with preserved ejection fraction patients with acute heart failure and dopamine: the ROPA-DOP trial. JACC Heart Fail 6(10):859\u2013870. https:\/\/doi.org\/10.1016\/j.jchf.2018.04.00863","journal-title":"JACC Heart Fail"},{"key":"614_CR63","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/eurheartj\/ehu320","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Tang WH, Testani JM, McMurray JJ (2014) Terminology and definition of changes renal function in heart failure. Eur Heart J 35:3413\u20133416","journal-title":"Eur Heart J"},{"key":"614_CR64","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.cnur.2018.07.001","volume":"380","author":"R Bellomo","year":"2012","unstructured":"Bellomo R, Kellum JA, Ronco C (2012) Acute kidney injury. Lancet 380:756\u2013766. https:\/\/doi.org\/10.1016\/j.cnur.2018.07.001","journal-title":"Lancet"},{"key":"614_CR65","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00000658-197311000-00009","volume":"178","author":"SM Baek","year":"1973","unstructured":"Baek SM, Brown RS, Shoemaker SW (1973) Early prediction of acute renal failure and recovery. II Renal function response to furosemide. Ann Surg 178:605\u2013608","journal-title":"Ann Surg"},{"key":"614_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/cc13015","volume":"17","author":"LS Chawla","year":"2013","unstructured":"Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG (2013) Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 17:8\u201310. https:\/\/doi.org\/10.1186\/cc13015","journal-title":"Crit Care"},{"key":"614_CR67","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1681\/ASN.2014060535","volume":"26","author":"JL Koyner","year":"2015","unstructured":"Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Bennett MR, Kimmel PL, Seneff MG, Chawla LS (2015) Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol 26:2023\u20132031. https:\/\/doi.org\/10.1681\/ASN.2014060535","journal-title":"J Am Soc Nephrol"},{"key":"614_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-018-2021-1","volume":"22","author":"N Lumlertgul","year":"2018","unstructured":"Lumlertgul N, Peerapornratana S, Trakarnvanich T, Pongsittisak W, Surasit K, Chuasuwan A, Tankee P, Tiranathanagul K, Praditpornsilpa K, Tungsanga K, Eiam-Ong S, Kellum JA, Srisawat N, FST Study Group (2018) Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Crit Care 22:1\u20139. https:\/\/doi.org\/10.1186\/s13054-018-2021-1","journal-title":"Crit Care"},{"key":"614_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/CCM.0b013e318195424d","volume":"37","author":"PH van der Voort","year":"2009","unstructured":"van der Voort PH, Boerma EC, Koopmans M, Zandberg M, de Ruiter J, Gerritsen RT, Egbers PH, Kingma WP, Kuiper MA et al (2009) Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Crit Care Med 37:533\u2013538. https:\/\/doi.org\/10.1097\/CCM.0b013e318195424d","journal-title":"Crit Care Med"},{"key":"614_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/cc13871","volume":"18","author":"PHJ Van der Voort","year":"2014","unstructured":"Van der Voort PHJ, Boerma EC, Pickkers P (2014) The furosemide stress test to predict renal function after continuous renal replacement therapy. Crit Care 18:6\u20137. https:\/\/doi.org\/10.1186\/cc13871","journal-title":"Crit Care"},{"issue":"1","key":"614_CR71","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13613-018-0355-0","volume":"8","author":"R Matsuura","year":"2018","unstructured":"Matsuura R, Komaru Y, Miyamoto Y, Yoshida T, Yoshimoto K, Isshiki R, Mayumi K, Yamashita T, Hamasaki Y, Nangaku M, Noiri E, Morimura N, Doi K (2018) Response to different furosemide doses predicts AKI progression in ICU patients with elevated plasma NGAL levels. Ann Intensive Care 8(1):8","journal-title":"Ann Intensive Care"},{"key":"614_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/1354750X.2017.1387934","volume":"23","author":"BA McMahon","year":"2018","unstructured":"McMahon BA, Koyner JL, Novick T, Menez S, Moran RA, Lonze BE, Desai N, Alasfar S, Borja M, Merritt WT, Ariyo P, Chawla LS, Kraus E (2018) The prognostic value of the furosemide stress test in predicting delayed graft function following deceased donor kidney transplantation. Biomarkers 23:61\u201369","journal-title":"Biomarkers"},{"key":"614_CR73","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40620-018-0539-6","volume":"31","author":"SJ Klein","year":"2018","unstructured":"Klein SJ, Lehner GF, Forni LG, Joannidis M (2018) Oliguria in critically ill patients: a narrative review. J Nephrol 31:855\u2013862. https:\/\/doi.org\/10.1007\/s40620-018-0539-6","journal-title":"J Nephrol"},{"key":"614_CR74","doi-asserted-by":"publisher","first-page":"172","DOI":"10.11622\/smedj.2014130","volume":"15","author":"JR Prowle","year":"2011","unstructured":"Prowle JR, Liu YL, Licari E, Bagshaw SM, Egi M, Haase M, Haase-Fielitz A, Kellum JA, Cruz D, Ronco C, Tsutsui K, Uchino S, Bellomo R (2011) Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care 15:172. https:\/\/doi.org\/10.11622\/smedj.2014130","journal-title":"Crit Care"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00614-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:10Z","timestamp":1777564570000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/32\/6\/883\/8328166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00614-1","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The manuscript has not been published previously except in the abstract form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical responsibilities"}}]}}